Venture Capital

BioScience Managers Translation Fund I

Investment Details

Investor Type
Venture Capital

Asset Class Focus
Venture Capital

Stage Focus
Early Stage, Seed, Series A, Series B

Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, China, France, Italy, Denmark, Switzerland, Spain, South Korea, Turkey, Netherlands, Sweden, Belgium, Norway, Finland

Industries Focus

  • Healthcare
  • Digital Health
  • Pharmaceuticals
  • Medical Devices
  • Diagnostics
  • Biotechnology
  • Medical Research
  • Medical Equipment
  • Medical Technology
  • Health IT
  • Medical Services
  • Medical Supplies
  • Medical Research Institutions
  • Genomic Medicine
  • Paediatrics

Investment Size:
10,000,000 to 100,000,000 USD

Investor Details Founded: 2003

BioScience Managers Translation Fund I is a prominent Australian venture capital firm specializing in early-stage investments within the life sciences sector. The fund focuses on identifying and supporting innovative companies that have the potential to transform healthcare through advancements in biotechnology, medical devices, digital health, and pharmaceuticals. By providing strategic vision and practical support, BioScience Managers aims to accelerate the development and commercialization of biomedical discoveries, ultimately improving patient outcomes and advancing the healthcare industry.

The fund's investment strategy targets private and public healthcare companies with clear technological and market advantages, regardless of location. BioScience Managers seeks to partner with strong management teams and actively engage in the growth and success of these companies. The firm's expertise spans various sectors, including genomic medicine, paediatrics, and digital technologies, enabling them to invest in high-value areas with significant unmet medical needs in global markets.

With a strong track record in funds management, BioScience Managers has demonstrated a commitment to delivering exceptional investment returns. Their previous funds have achieved annual internal rates of return between 22% and 40%, encompassing investments in pharmaceuticals, medical devices, diagnostics, and digital health technologies. This history underscores their ability to identify and nurture companies that can become international leaders in the biomedical sector, contributing to the growth and innovation of Australia's biomedical industry.

Requirements
  • Early-stage life sciences companies with innovative technologies
  • Strong management teams
  • Clear technological and market advantages
  • Potential for significant impact on healthcare outcomes
Contact

[Official Website Hidden]

[HQ Location Hidden]

[Email Hidden]

[Contact Number Hidden]

Portfolio Companies
  • Closed Loop Medical
  • Adherium
  • Cynata Therapeutics Ltd
Claim this Investor

Are you an official representative of BioScience Managers Translation Fund I?

Claim this investor to update information, manage your profile, and get a verified seal.

Claim